Cargando…

Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell disorders with a poor prognosis, especially for elderly patients. Increasing evidence suggests that alterations in the non-hematopoietic microenvironment (bone marrow niche) can contribute to or initi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weickert, Marie-Theresa, Hecker, Judith S., Buck, Michèle C., Schreck, Christina, Rivière, Jennifer, Schiemann, Matthias, Schallmoser, Katharina, Bassermann, Florian, Strunk, Dirk, Oostendorp, Robert A. J., Götze, Katharina S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961144/ https://www.ncbi.nlm.nih.gov/pubmed/33723276 http://dx.doi.org/10.1038/s41598-021-85122-8

Ejemplares similares

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
por: Lang, Jonas B., et al.
Publicado: (2022)

Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS
por: Buck, Michèle C., et al.
Publicado: (2023)

Autophagy in mesenchymal progenitors protects mice against bone marrow failure after severe intermittent stress
por: Landspersky, Theresa, et al.
Publicado: (2022)

Secreted factors from mouse embryonic fibroblasts maintain repopulating function of single cultured hematopoietic stem cells
por: Marquez, Romero, et al.
Publicado: (2020)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

IRAK1: oncotarget in MDS and AML
por: Beverly, Levi J., et al.
Publicado: (2014)

Computational modeling of stem and progenitor cell kinetics identifies plausible hematopoietic lineage hierarchies
por: Bast, Lisa, et al.
Publicado: (2021)

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
por: Garz, Anne-Kathrin, et al.
Publicado: (2017)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Age-related epigenetic drift in the pathogenesis of MDS and AML
por: Maegawa, Shinji, et al.
Publicado: (2014)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
por: Jilg, Stefanie, et al.
Publicado: (2019)

Choosing the source of healthy controls for studies on myeloid malignancies: all bone marrow cells are created equal, but some are more equal than others
por: Rivière, Jennifer, et al.
Publicado: (2023)

Upregulation of mitotic bookmarking factors during enhanced proliferation of human stromal cells in human platelet lysate
por: Laner-Plamberger, Sandra, et al.
Publicado: (2019)

American Society of Hematology 2020 Podcast Collection: MDS and AML
por: Almeida, António
Publicado: (2021)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
por: Jensen, Oda, et al.
Publicado: (2022)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
por: Bhatnagar, Udit Bhaskar, et al.
Publicado: (2016)

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy
por: Uy, Geoffrey L., et al.
Publicado: (2016)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
por: Raza, Azra, et al.
Publicado: (2020)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML
por: Przychodzen, Bartlomiej, et al.
Publicado: (2017)

Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
por: Menshawy, Nadia El, et al.
Publicado: (2020)

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
por: Rio-Machin, Ana, et al.
Publicado: (2020)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
por: Chang, Lixian, et al.
Publicado: (2022)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
por: Li, Hongjiao, et al.
Publicado: (2023)

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
por: Baer, Constance, et al.
Publicado: (2023)

Heparin Differentially Impacts Gene Expression of Stromal Cells from Various Tissues
por: Laner-Plamberger, Sandra, et al.
Publicado: (2019)

Heparin and Derivatives for Advanced Cell Therapies
por: Laner-Plamberger, Sandra, et al.
Publicado: (2021)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

Extra-hematopoietic immunomodulatory role of the guanine-exchange factor DOCK2
por: Scharler, Cornelia, et al.
Publicado: (2022)

Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications
por: Möröy, Tarik, et al.
Publicado: (2019)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML
por: Huang, Feiteng, et al.
Publicado: (2020)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
por: Snow, Anson, et al.
Publicado: (2022)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7nvkvlcq56k2ej7nvm3q6b3aq5